Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies.
Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulias V. Mavroudis D, et al. Among authors: kosmatopoulos k. Oncology. 2006;70(4):306-14. doi: 10.1159/000096252. Epub 2006 Oct 12. Oncology. 2006. PMID: 17047402 Clinical Trial.
Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D. Bolonaki I, et al. Among authors: kosmatopoulos k. J Clin Oncol. 2007 Jul 1;25(19):2727-34. doi: 10.1200/JCO.2006.10.3465. J Clin Oncol. 2007. PMID: 17602077 Clinical Trial.
Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.
Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D. Kotsakis A, et al. Among authors: kosmatopoulos k. Ann Oncol. 2012 Feb;23(2):442-9. doi: 10.1093/annonc/mdr396. Epub 2011 Aug 25. Ann Oncol. 2012. PMID: 21873272 Free article. Clinical Trial.
Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulias V, Mavroudis D. Vetsika EK, et al. Among authors: kosmatopoulos k. Cancer Immunol Immunother. 2012 Feb;61(2):157-168. doi: 10.1007/s00262-011-1093-4. Epub 2011 Aug 20. Cancer Immunol Immunother. 2012. PMID: 21858533
Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulias V, Mavroudis D. Vetsika EK, et al. Among authors: kosmatopoulos k. J Immunother. 2011 Nov-Dec;34(9):641-50. doi: 10.1097/CJI.0b013e31823284a6. J Immunother. 2011. PMID: 21989412
A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics.
Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C. Georgoulias V, et al. Among authors: kosmatopoulos k. Clin Lung Cancer. 2013 Jul;14(4):461-5. doi: 10.1016/j.cllc.2013.02.001. Epub 2013 May 4. Clin Lung Cancer. 2013. PMID: 23647738 Clinical Trial.
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, Kazarnowisz A, Korozan M, de Las Penas R, Majem M, Chella A, Griesinger F, Bournakis E, Sadjadian P, Kotsakis A, Chinet T, Syrigos KN, Correale P, Gallou C, Jamet JM, Vetsika EK, Kosmatopoulos K, Georgoulias V; Vx-001-201 trial team. Gridelli C, et al. Among authors: kosmatopoulos k. Br J Cancer. 2020 May;122(10):1461-1466. doi: 10.1038/s41416-020-0785-y. Epub 2020 Mar 25. Br J Cancer. 2020. PMID: 32210365 Free PMC article. Clinical Trial.
59 results